Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients

Journal of Inherited Metabolic Disease

Volumn 38, Issue 3, 2015, Pages 565-572

  Carlier, Pierre G ^a   Azzabou, Noura ^a   de Sousa, Paulo Loureiro ^a,b   Hicks, Arnaud ^a   Boisserie, Jean Marc ^a   Amadon, Alexis ^c   Carlier, Robert Yves ^d   Wary, Claire ^a   Orlikowski, David ^d   Laforêt, Pascal ^e  

^a DIF   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c NeuroSpin   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE;

ADULT; AGED; DISEASE COURSE; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; GLYCOGEN STORAGE DISEASE TYPE II; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; SKELETAL MUSCLE; YOUNG ADULT;

ADULT; AGED; ALPHA-GLUCOSIDASES; DISEASE PROGRESSION; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLE, SKELETAL; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84939947786     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-015-9825-9     Document Type: Article

References (25)

1. Arpan I, Forbes SC, Lott DJ et al (2013) T2 mapping provides multiple approaches for the characterization of muscle involvement in neuromuscular diseases: a cross-sectional study of lower leg muscles in 5-15-year-old boys with Duchenne muscular dystrophy. NMR Biomed 26:320–328
2. Azzabou N, Loureiro de Sousa P, Caldas E, Carlier PG (2014) Validation of a generic approach to muscle water T2 determination at 3T in fat-infiltrated skeletal muscle. J Magn Reson Imaging
3. Carlier PG (2014) Global T2 versus water T2 in NMR imaging of fatty infiltrated muscles: different methodology, different information and different implications. Neuromuscul Disord 24:390–392
4. Carlier PG, Azzabou N, de Sousa PL et al (2013) P.14.4 Diagnostic role of quantitative NMR imaging exemplified by 3 cases of juvenile dermatomyositis. Neuromuscul Disord 23:814
5. de Kerviler E, Leroy-Willig A, Jehenson P et al (1991) Exercise-induced muscle modifications: study of healthy subjects and patients with metabolic myopathies with MR imaging and P-31 spectroscopy. Radiology 181(1):259–264
6. Friedman SD, Poliachik SL, Otto RK et al (2013) Longitudinal features of stir bright signal in FSHD(1.). Muscle Nerve
7. Glover GH, Schneider E (1991) Three-point Dixon technique for true water/fat decomposition with B0 inhomogeneity correction. Magn Reson Med 18:371–383
8. Güngör D, Kruijshaar ME, Plug I et al (2013) Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 8:49–56
9. Hollingsworth KG, de Sousa PL, Straub V, Carlier PG (2012) Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris. France Neuromuscul Disord 22(Suppl 2):S54–S67
10. Hu HH, Börnert P, Hernando D et al (2012) ISMRM workshop on fat-water separation: insights, applications and progress in MRI. Magn Reson Med 68:378–388
11. 13C NMR spectroscopy. Neuromuscul Disord 1(2):99–101
12. Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8:160–171
13. Lamminen AE (1990) Magnetic resonance imaging of primary skeletal muscle diseases: patterns of distribution and severity of involvement. Br J Radiol 63:946–950
14. Ma J (2008) Dixon techniques for water and fat imaging. J Magn Reson Imaging 28:543–558
15. Ravaglia S, Pichiecchio A, Ponzio M et al (2010) Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response. J Inherit Metab Dis 33:737–745
16. Saab G, Thompson RT, Marsh GD (2000) Effects of exercise on muscle transverse relaxation determined by MR imaging and in vivo relaxometry. J Appl Physiol 88:226–233
17. Tardif-de Géry S, Vilquin J, Carlier P et al (2000) Muscular transverse relaxation time measurement by magnetic resonance imaging at 4 Tesla in normal and dystrophic dy/dy and dy(2j)/dy(2j) mice. Neuromuscul Disord 10:507–513
18. Thibaud J-L, Monnet A, Bertoldi D et al (2007) Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging. Neuromuscul Disord 17:575–584
19. Thurberg BL, Lynch Maloney C, Vaccaro C et al (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 86:1208–1220
20. Tofts PS (2003) Quantitative MRI of the brain: measuring changes caused by disease. Wiley, New York
21. Walter G, Cordier L, Bloy D, Sweeney HL (2005) Noninvasive monitoring of gene correction in dystrophic muscle. Magn Reson Med 54:1369–1376
22. Wattjes MP, Kley RA, Fischer D (2010) Neuromuscular imaging in inherited muscle diseases. Eur Radiol 20:2447–2460
23. Willcocks RJ, Arpan IA, Forbes SC et al (2014) Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: effects of age and disease progression. Neuromuscul Disord 24:393–401
24. Willis TA, Hollingsworth KG, Coombs A et al (2013) Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 8:e70993
25. Yarnykh VL (2007) Actual flip-angle imaging in the pulsed steady state: a method for rapid three-dimensional mapping of the transmitted radiofrequency field. Magn Reson Med 57:192–200